Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT01621243 is registered in ClinicalTrials.gov with Momenta Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01621243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01621243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Momenta Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2012
Completion date
October 24, 2016
Enrollment
128 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer